Protease-activated receptor

Protease-activated receptors (PARs) are a family of G protein-coupled receptors that are activated by proteases. These receptors play a crucial role in various physiological and pathological processes, including inflammation, coagulation, and tissue repair. Protease-activated receptors are unique among G protein-coupled receptors because they are activated by a proteolytic mechanism, where the protease cleaves part of the receptor itself, revealing a new N-terminus that acts as a tethered ligand and binds intramolecularly to activate the receptor.

Structure and Activation

Protease-activated receptors are composed of a single polypeptide chain that traverses the cell membrane seven times, characteristic of the G protein-coupled receptor family. The activation of PARs involves the cleavage of their extracellular N-terminal domain by specific proteases. This cleavage exposes a new N-terminal sequence that serves as a tethered activating ligand. The most well-known activators of PARs are thrombin, which activates PAR-1, PAR-3, and PAR-4, and trypsin and tryptase, which preferentially activate PAR-2.

Types and Functions

There are four known types of protease-activated receptors, designated PAR-1, PAR-2, PAR-3, and PAR-4. Each of these receptors has distinct but sometimes overlapping patterns of expression and activation by different proteases.

• PAR-1: Widely expressed in various cell types, including platelets, endothelial cells, and smooth muscle cells, and is involved in thrombosis, inflammation, and vascular development.
• PAR-2: Found in the gastrointestinal tract, skin, and respiratory system, playing roles in inflammation, pain, and tissue repair.
• PAR-3: Has a more limited expression pattern and is involved in thrombin signaling in a cooperative manner with PAR-4.
• PAR-4: Expressed in platelets and some other cell types, contributing to thrombosis and coagulation.

Clinical Significance

The activation of PARs has been implicated in a variety of diseases, including cancer, asthma, arthritis, and cardiovascular diseases. Due to their involvement in these processes, PARs represent potential therapeutic targets. For example, inhibitors of PAR-1 have been explored for their antithrombotic properties in the prevention of myocardial infarction and stroke.

Research and Therapeutic Approaches

Research into protease-activated receptors has focused on understanding their role in disease and developing drugs that can modulate their activity. Antagonists and agonists of PARs are being investigated for their potential to treat various conditions, such as inflammation, pain, and thrombosis. The challenge in developing therapies targeting PARs lies in achieving specificity and avoiding side effects, given the widespread expression and multifaceted roles of these receptors.

‎